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NUCB2 is an EF-hand Ca
2+ binding protein that has been
implicated in various physiological processes like calcium
homeostasis, hypothalamic regulation of feeding and TNF
receptor shedding. In our previous study we identified NUCB2
as a potential tumour antigen eliciting autoantibody respons-
es in 5.4% of gastric cancer patients but not in the healthy
individuals.The current study aimed to elucidate the molecu-
lar mechanism underlying NUCB2 immunogenicity and to gain
an insight into the physiological functions of NUCB2 in the
stomach. mRNA expression analysis demonstrated that
NUCB2 is ubiquitously expressed in normal tissues, including
lymphoid tissues, and downregulated in gastric tumours when
compared with the adjacent relatively normal stomach tis-
sues.The search for molecular alterations resulted in the iden-
tification of novel mRNA variants transcribed from an alterna-
tive promoter and expressed predominantly in gastric cancers.
Western blot analysis demonstrated that the protein levels cor-
respond to mRNA levels and revealed that NUCB2 is phospho-
rylated in gastric mucosa.Furthermore,a 55 kDa isoform,gen-
erated presumably by yet an unidentified post-translational
modification was detected in gastric tumours and AGS gastric
cancer cells but was absent in the relatively normal gastric
mucosa and thereby might have served as a trigger for the
immune response against NUCB2. Staining of stomach tissue
microarray with anti-NUCB2 antibody revealed that it is
expressed in the secretory granules of chief cells and in the
cytoplasm of parietal cells in the functioning gastric glands
which are lost in atrophic glands and tumour cells. Hence we
propose that NUCB2 may be implicated in gastric secretion by
establishing an agonist-releasable Ca
2+ store in ER or Golgi
apparatus, signalling via heterotrimeric Gα proteins and/or
mediating the exocytosis of the secretory granules.
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N
ucleobindin 2 (NUCB2 or NEFA) is a ubiq-
uitously expressed EF-hand Ca
2+ binding
protein that may be implicated in various
physiological processes, however, its functional
role and mechanism of action are poorly under-
stood. So far, two nucleobindins – NUCB1 (or
Calnuc, Nuc) and NUCB2 have been identified in
humans (Wendel et al. 1995; Barnikol-Watanabe
et al. 1994).They share 61.65% amino acid iden-
tity and a characteristic composition of functional
domains – a signal peptide, a Leu/Ile rich region,
basic amino acid rich region including putative
bipartite nuclear localisation signal,two Ca
2+ bind-
ing EF-hand domains separated by acidic amino
acid rich region and a leucine zipper (Figure 1)
(Barnikol-Watanabe  et al. 1994; Miura  et al.
1992). Genes encoding NUCB1 and NUCB2 are
located in 19q13.2-q13.4 and 11p15.1-p14,
respectively, and are deemed to be derived from a
common four-domain EF-hand ancestor
(Karabinos et al. 1996). Within the cell both are
located in the cytoplasmic and Golgi luminal
pools, both are secreted into extracellular space
and interact with other proteins in a calcium-
dependent manner (Lavoie et al. 2002; Lin et al.
2000; Morel-Huaux et al. 2002;Taniguchi et al.
2000;Islam et al. 2006).Both nucleobindins were
reported to interact with the postmitotic growth
suppressor Necdin in neuronal cytoplasm
(Taniguchi et al. 2000) and have been shown to
constitute a Ca
2+ storage pool in Golgi (Lin et al.
1999; Kroll  et al. 1999; Morel-Huaux  et al.
2002). NUCB1 interacts with cyclooxygenases in
COS-1 cells (Ballif et al. 1996) and with G protein
Gαi3 in the cytoplasm of rat kidney cells (Lin et
al. 2000), and acts as a negative regulator in
ATF6-mediated unfolded protein response
(Tsukumo et al. 2007). It is secreted via constitu-
tive secretory pathway in AtT20 pituitary cells
(Lavoie et al. 2002). NUCB2 has been shown to
ORIGINAL PAPERform a calcium-dependent complex with ARTS-1
that mediates release of TNF receptor to the
extracellular compartment from human vascular
endothelial cells (Islam et al. 2006).
Furthermore,nesfatin-1 – the N terminal 82 amino
acid peptide generated by post-translational pro-
cessing of NUCB2 in rat hypothalamus – was
recently shown to be involved in feeding regulation
and suggested to suppress appetite via leptin-inde-
pendent signalling (Oh et al. 2006) and is upreg-
ulated by serotonin receptor agonists (Nonogaki
et al. 2008).
In a previous study we identified NUCB2 as an
antigen eliciting autoantibody production in gas-
tric cancer patients (Line et al. 2002) by exploit-
ing the SEREX (serological identification of anti-
gens by recombinant expression cloning) approach
(Sahin et al. 1997).The screening of gastric can-
cer-derived cDNA expression library with allo-
geneic serum resulted in the identification of 5
different serum-reactive phage clones, including
Zg4 encoding the 31-179 aa region of NUCB2
(Figure 1). Anti-NUCB2 antibodies were found
exclusively in patients with gastric cancer and not
in colon and breast cancer patients or healthy
donors. No immune responses against NUCB2
have been reported so far, while NUCB1 has been
shown to be overexpressed in 59.4% of colon can-
cer specimens and elicit autoantibody responses in
11.5% of the cases (Chen et al. 2007).
Furthermore, Nucb1 is excessively produced in
lupus-prone mice and induces autoantibody
response against itself and a number of other
lupus-associated autoantigens when injected in
normal BALB/c mice,and the antibody production
is mediated by autoreactive CD4
+T cells (Kanai et
al. 1995;Kubota et al. 2001).
The aim of the current study is to identify the
putative molecular alterations underlying the
immunogenicity of NUCB2 in gastric cancer
patients and to get an insight into its physiological
role in gastric mucosa.
Materials and Methods
Tissue and serum samples and cell line
Gastric cancer and adjacent relatively normal
tissue samples from 36 patients (Table 1) under-
going surgery at the Latvian Oncology Centre
were collected intraoperatively and one part of
each specimen was immediately submerged in
RNAlater (Ambion) and subsequently used for
RNA extraction while another was embedded in
paraffin blocks. Sera were collected from the
same patients whose tissue specimens were col-
lected and from another 20 gastric cancer
patients, 23 colorectal and 11 breast cancer
patients and 13 patients with chronic atrophic
gastritis at the time of diagnosis. Sera from 36
healthy individuals were obtained from the
Genome Database of the Latvian population.This
study was approved by the Central Committee of
Medical Ethics of Latvia and the tissue samples
and sera were collected after the patients’
informed consent was obtained.
AGS gastric cancer cell line was purchased from
ECACC and grown in monolayer culture in Ham's
F12 supplemented with 2 mM glutamine and
10% FBS (Invitrogen).
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Figure 1. The schematic representation of NUCB2 exon composition and the functional domains of the protein. Sp, signal peptide; Leu/Ile,
Leu and Ile rich region; B, basic amino acid rich region; NLS, putative bipartite nuclear localisation signal; EF1, EF2, Ca
2+ binding EF-hand
domains; A, acidic amino acid rich region; L, leucine zipper; Hy, hydrophobic region.
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The frequency of anti-NUCB2 antibody respons-
es in allogeneic sera was determined by plaque
assay as described previously (Line et al. 2002).
Briefly,E. coli XL1 blue cells were transfected with
the lambda phages by spotting 20-30 pfu of Zg4
phage side by side with non-recombinant phage
directly on an agar plate and the phage arrays were
screened with 1:200 diluted sera, which have been
previously preabsorbed with E. coli-phage lysates.
The presence of antibodies against gastric pari-
etal cell (GPC) H+/K+ ATPase antigen was tested
semi-quantitatively in the sera from 13 atrophic
gastritis patients and 16 gastric cancer patients by
enzyme linked immunosorbent assay exploiting
AUTOSTAT™ Anti-Gastric Parietal Cell kit (Hycor
Biomedical) following manufacturer’s instructions.
Real-time RT-PCR analysis
NUCB2 mRNA expression pattern was analysed
in a panel of normal tissues consisting of whole
bone marrow, brain, colon, heart, kidney, lung, pan-
creas, skin, spleen, stomach, testis, thymus and tra-
chea (BioCat,Ambion) and compared between gas-
tric cancer and adjacent non-cancerous tissues by
real-time RT-PCR. Total RNA was isolated from
RNAlater preserved cancerous and adjacent nor-
mal tissue specimens using TRI reagent (Sigma)
according to the manufacturer’s instructions. Four
micrograms of total RNA were used to synthesise
first-strand cDNA by random hexamer priming
using First-Strand cDNA Synthesis Kit (MBI
Fermentas). To choose the appropriate reference
genes for each tissue panel,a set of seven candidate
reference genes (TBP, POLR2A, YWHAZ, ACTB,
GAPDH, PGK1, TUB3A) were tested for their
mRNA expression stability in the given panel and
three most stable genes (TUB3A, ACTB and
POLR2A for normal tissue panel and ACTB,TBP
and POLR2A for gastric cancer and the adjacent
tissue panel) were determined by using the open-
access software GeNorm (http://medgen.ugent.be/
~jvdesomp/genorm).These genes were used to cal-
culate the factor which was applied for the normal-
isation of the obtained NUCB2 mRNA expression
data.The following gene-specific primers were used
for the amplification of NUCB2 and the reference
genes: NUCB2 forward 5’-TCAAGCAAGT-
GATTGATGTGC-3’, reverse 5’-TCAGGATTCA
GGTGGTTTAGG-3’; ACTB forward 5’-AGTGT-
GACGTGGACATCCG-3’, reverse 5’-AATCTCATC
TTGTTTTCTGCGC-3; TUB3A forward 5’-TATG-
GCAAGAAGTCCAAGCTG-3’,reverse 5’-TACCAT-
GAAGGCACAATCAGAG-3’; POLR2A forward 5’-
GGGTCATCTTCCCAACTGGAG-3’, reverse 5’-
CACCAGCTTCTTGCTCAATTCC-3’ and TBP for-
ward 5’-CCACTCACAGACTCTCACAAC-3’,
reverse 5’-CTGCGGTACAATCCCAGAAC-3’. In all
experiments 1/30 of each RT mixture was amplified
in a total reaction volume of 20 µL containing 2
pmol of each primer and 10 µL SYBR Green mix
(ABgene) exploiting 7500 Real Time PCR System
(Applied Biosystems).All reactions were performed
in duplicates.
5’ RLM-RACE and RT-PCR analysis
Full-length 5’ end sequences of NUCB2 cDNA
were cloned from 3 gastric cancer specimens using
FirstChoice
TM RLM-RACE kit (Ambion) as recom-
mended by the manufacturer.Briefly,10 µg of total
RNA underwent 5’ phosphate removal from
uncapped RNAs by Calf Intestinal Phosphatase
treatment and next, cap structures from full-length
mRNAs were removed with Tobacco Acid
Pyrophosphatase leaving a free 5’ phosphate.
mRNA molecules containing 5’ phosphate were
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Table 1. Clinicopathological characteristics of the gastric can-
cer patients.
Variables Number (%)
Total 36 (100%)
Sex
Male 15 (41.7)
Female 21 (58.3)
Age (years) 
Mean (range) 66 (34-85)
Tumour location
Upper third 1 (2.8)
Middle third 18 (50)
Lower third 13 (36)
Total 1 (2.8)
Not determined 3 (8.4)
Grade
G1 1 (2.8)
G2 6 (16.7)
G3 21 (58.3)
G4 5 (14)
Not determined 3 (8.4)
Tumour stage 
IA 5 (14)
IB 1 (2.8)
II 12 (33.3)
IIIA 14 (39)
IV 2 (5.6)
Not determined 2 (5.6)subjected to the ligation of RNA adapters to their
5’ ends. Random-primed reverse transcription was
performed with subsequent nested PCR using
NUCB2-specific reverse primers (5’-TCAGGATT
CAGGTGGTTTAGG-3’ for PCR 1 and 5’-CTAT-
GTCTGCTTTCTGGAGC-3’ for PCR 2) and
adapter-specific forward primers. PCR products
were cloned using InsTAclone
TM PCR Product
cloning Kit (MBI Fermentas) and multiple clones
were sequenced. The expression of the identified
NUCB2 transcript variants in normal tissues
(brain, liver, heart, kidney, lung, trachea, spleen,
colon, stomach, testis and ovary) (Ambion) and
paired gastric cancer and adjacent normal tissues
was analysed by RT-PCR using alternative forward
primers located in exon 1 5’-CAGGTTTGT-
GCGCTGGACG-3’and in exon 1a 5’-AGAAATCTC-
CTGGAATCAAGG-3’ and common reverse primer
5’-CTATGTCTGCTTTCTGGAGC-3’. GAPDH was
used as the endogenous control.cDNA synthesis was
carried out as described above and 1/15 of RT mix-
ture was amplified in a total reaction volume of 20
µL containing 10 pmol of each primer, 200 µM
dNTPs and 2 U of Taq polymerase (MBI
Fermentas) in the following cycling conditions: 1
min at 94°C,30 s at 58°C and 45 s at 72°C.Twenty
five cycles of amplification were performed for
GAPDH,27 for NUCB2 transcripts containing exon
1 and 35 for those containing exon 1a.
Western blot analysis
NUCB2 protein levels in gastric cancer, adjacent
normal tissues and AGS cell line were analysed by
Western blotting. Total protein was isolated from
tissue samples using TRI reagent (Sigma) simulta-
neously with RNA according to manufacturer’s
instructions.Ten µg of total protein were resuspend-
ed in Laemmli sample buffer,denatured for 5 min at
100°C and separated by 10% SDS-PAGE.Proteins
were electroblotted onto Protan nitrocellulose
membrane (Whatman) and stained with Ponceau S
solution to verify equal protein loading. The mem-
brane was destained, blocked with 5% (w/v) fat-
free milk in TBS and probed with 1:200 diluted
mouse anti-NUCB2 monoclonal antibody, kindly
provided by Dr. Shitsu Barnikol-Watanabe
(Gottingen, Germany). Antigen-antibody complexes
were detected using HRP-conjugated goat anti-
mouse secondary antibody (Sigma) (diluted 1:5000
in TBS) and ECL detection system (GE Healthcare)
according to the manufacturer’s instructions. In
parallel, secondary antibody alone was used for
probing to provide the negative control.
Dephosphorylation and deglycosylation experiments
On-line open access softwares (http://www.
cbs.dtu.dk/services and http://www.expasy.ch/tools)
were used for the prediction of protein phosphory-
lation and glycosylation sites. To assess the phos-
phorylation status, protein samples were treated
with 1 U of SAP (MBI Fermentas) for 1 h at 37°C
and then subjected to Western blot analysis as
described above. Deglycosylation was carried out
using Enzymatic deglycosylation kit (Glyko)
according to the manufacturer’s instructions. The
protein extracts were denatured by heating at
100°C for 5 min in SDS and β-mercaptoethanol
and then incubated with N-Glycanase (5U/mL),
Sialidase A (5U/mL), O-Glycanase (1.25U/mL),
β(1-4)-Galactosidase (2 U/mL) and β-N-Ace-
tylglucosaminidase (40 U/mL) for 3 hours at 37°C
and analysed by Western blot. Bovine Fetuin was
treated in parallel as a positive control.
Immunohistochemistry 
To investigate the NUCB2 expression in different
regions of stomach and various gastric lesions,
human tissue array containing a total of 63 cores
from multiple sites in normal stomach, and a total
of 80 cores from superficial gastritis,mild,moder-
ate and severe chronic atrophic gastritis with
intestinal metaplasia as well as grade I-III adeno-
carcinoma was purchased from Cybrdi and
processed using mouse anti-NUCB2 monoclonal
antibody (at 1:20 dilution in PBS,1% BSA) kind-
ly provided by Dr. Shitsu Barnikol-Watanabe
(Gottingen, Germany) and Mouse UniTec ABC kit
(Calbiochem) according to the manufacturer’s
instructions.To study NUCB2 protein expression in
gastric cancers,4 µm thick sections were prepared
from formalin-fixed, paraffin-embedded gastric
cancer and adjacent normal tissue specimens from
the same patients whose tissues were used for RT-
PCR and Western blot analyses and mounted on
poly-L-lysine-coated slides, deparaffinised in
xylene and rehydrated by placing in 100%, 95%,
80%, 70%, 50% ethanol and PBS. Antigen
retrieval was performed by boiling in microwave in
10 mM sodium citrate buffer for 15 min.Next,the
sections were washed in PBS and the endogenous
peroxidases were quenched with 0.3% hydrogen
peroxide in methanol for 30 min at RT. Then the
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sections were blocked with 5% BSA in PBS,0.5%
Tween-20 for 1 h and incubated with mouse anti-
NUCB2 monoclonal antibody, at 1:20 dilution in
PBS, 1% BSA overnight at 4°C. Slides were
washed in PBS,0.1% Tween-20 and then incubat-
ed with HRP-conjugated goat anti-mouse second-
ary antibody (Sigma) at 1:100 dilution for 1 h at
RT. To visualise antigen-antibody complexes, sec-
tions were stained for 10 min with DAB solution
(Sigma) and counterstained with Mayer’s haema-
toxylin. Sections were dehydrated in 70%, 96%
and 100% ethanol for 3 min each, cleared in car-
boxylol and covered with mounting balsam and
cover slips. In parallel, negative controls were per-
formed by substituting primary antibody with non-
immunised mouse serum.
Results
Humoural responses to NUCB2 are gastric cancer-
specific 
The frequency of autoantibodies against NUCB2
was determined by plaque assay in the sera from
healthy individuals (n=36) and patients of gastric
cancer (n=56), colorectal cancer (n=23), breast
cancer (n=11) and chronic atrophic gastritis
(n=13). Anti-NUCB2 antibodies were found in 3
gastric cancer patients (5.36%), including the
patient whose serum was used for searching of
tumour antigens by allogeneic SEREX screening
but not in the healthy individuals and patients with
colorectal or breast cancer or gastritis (χ
2 test:
p=0.158 relative to healthy donors).
NUCB2 mRNA is differentially expressed in normal
tissues and downregulated in gastric cancer
NUCB2 mRNA expression pattern was examined
by real-time RT-PCR in a panel of RNAs derived
from various normal tissues and gastric cancer and
adjacent normal tissues (Table 1).This demonstrat-
ed that NUCB2 mRNA is predominantly expressed
in pancreas, while its level is 2-3 fold lower in
spleen, thymus, bone marrow, testis and stomach
and more than 8 fold lower in the remaining normal
tissues analysed (Figure 2 A). The comparison of
mRNA levels between paired gastric cancer and
relatively normal tissues showed that it is 2-95 fold
downregulated in 28 out of 36 cases analysed
(Figure 2 B). The difference between the mean
expression values in cancers and normal tissues was
statistically significant (0.35±0.23 vs 2.15±2.04,
paired t-test p=0.045). No correlation between the
expression level and tumour location, grade or
stage was observed.
5’ RLM–RACE analysis reveal novel NUCB2 tran-
script variants
To search for alternative transcription and trans-
lation initiation sites and splice variants of NUCB2,
5’ RLM-RACE analysis was performed resulting in
the identification of three novel transcript variants
of NUCB2 differing in the exon composition at the
5’ end of the mRNA (transcript variants b, c and d
in Figure 3 A) (deposited in GenBank, accession
numbers EU039831,EU039832 and EU039833).
Identification of an alternative first 134 bp exon
(1a) located 7408 bp upstream from the conven-
tional first exon suggests the existence of a distal
NUCB2 promoter.The other transcript variants dif-
fer in an alternative 5’splice site of the exon 1 that
is elongated by 20 bp, and an insertion of alterna-
tive exon 2a between exons 2 and 3.Although alter-
native exons 1a and 2a introduce two independent
upstream translation initiation sites, they are fol-
lowed by coterminous stop codons and therefore
Figure 2. The real-time RT-PCR analysis of NUCB2 mRNA expres-
sion in (A) a panel of normal tissue RNAs and (B) paired gastric
cancer (T, only selected cases shown) and adjacent relatively
normal tissues (N). BM, bone marrow. 
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Bcan not give rise to alternative protein isoforms
(Figure 3 A).
The expression of the NUCB2 transcript variants
a and b representing proximal and distal promoters,
respectively, was examined by RT-PCR in various
normal tissues and gastric cancer and adjacent nor-
mal tissues from seven patients.This demonstrated
that in the normal tissues the distal promoter is
used mainly in testis and ovary (Figure 3 B).
However, as its detection required 35 cycles of
amplification while NUCB2-a was detectable after
27 cycles, it likely is a low-abundance transcript
variant. This is also consistent with the results of
Northern blot revealing a single NUCB2-specific
band (data not shown).Usage of the distal promot-
er was also detected in more than a half of gastric
tumours analysed while it was low or undetectable
in the adjacent normal tissues (Figure 3 C).
Interestingly,with a single exception,the expression
of NUCB2-b transcripts was higher in the tumours
with markedly reduced NUCB2-a expression.
Western blot analysis reveal posttranslational
modifications of NUCB2
In order to determine whether the NUCB2 pro-
tein level corresponds to its mRNA level, protein
extracts of 16 paired gastric cancer and adjacent
normal tissues were analysed by Western blot.This
showed that the mRNA level correlated with the
protein level in all cases analysed and confirmed the
downregulation of NUCB2 in cancerous tissues
(Figure 4 A). It also revealed the presence of addi-
tional 52, 53, 55 and 57 kDa species of NUCB2,
furthermore 55 and 57 kDa bands were present in
9 out of 16 tumour tissue specimens, including
Ga3T – tumour tissue from the patient whose
serum was used to search for antigens by SEREX,
and AGS gastric cancer cells but not in the relative-
ly normal stomach tissues. Since no putative pro-
tein isoforms generated by alternative splicing were
identified,we concluded that these bands likely rep-
resent post-translationally processed forms of
NUCB2. To identify the nature of these modifica-
tions, NUCB2 sequence was analysed using tools
for the prediction of post-translational modifica-
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Figure 3. The identification of novel NUCB2 transcript variants by
5’RLM-RACE. (A) The schematic representation of exon-intron
composition at the 5’ end of NUCB2 gene (NC_000011.8),
NUCB2 mRNA reference sequence (NM_005013.2) and newly
identified transcript variants (b-c, GenBank accession nos.
EU039831-EU039833). The proximal promoter is located
upstream of exon 1, the newly identified distal promoter is locat-
ed upstream of exon 1a. The horizontal arrows indicate the sites
of primers used in the expression analysis. The analysis of pro-
moter usage in various normal tissues (B) and paired gastric can-
cer and adjacent normal tissues (C) by RT-PCR. NUCB2-a repre-
sents proximal promoter found in the reference sequence,
NUCB2-b – alternative distal promoter. The upper band detected
in testis, ovary and Ga39T tissues represents the transcript vari-
ant containing exon 2a. 27 and 35 PCR cycles were preformed
for amplification of transcript variants a and b, respectively.
GAPDH was amplified as the internal control using 25 cycles of
amplification.
Figure 4. Western blot analyses of NUCB2 expression. (A)
NUCB2 was downregulated in the majority of gastric cancer
specimens in comparison with adjacent normal tissue and the
protein levels correlated with the mRNA levels in all cases. Two
to 4 closely spaced bands that migrate in the range between 50
and 57 kDa were detected in gastric tissue specimens (molecu-
lar weight of the mature NUCB2 is ~50 kDa). (B) The treatment
of protein extracts with shrimp alkaline phosphatase (SAP)
revealed that 53 and 52 kDa bands in normal tissues and 52 and
57 kDa bands in tumour tissue represented phosphorylated forms
of NUCB2. 55 and 57 kDa bands were present only in the tumour
tissues, including Ga3T – tumour tissue from the patient with
anti-NUCB2 autoantibodies and AGS gastric cancer cells.
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tions at www.expasy.ch/tools/ and www.cbs.dtu.dk/
services. NetPhos 2.0 Server revealed a number of
putative Ser,Thr and Tyr phosphorylation sites.To
examine the phosphorylation status of NUCB2, the
protein extracts were treated with shrimp alkaline
phosphatase and subjected to Western blot analysis
(Figure 4 B). The treatment removed 53 and 52
kDa bands in normal tissues and 52 and 57 kDa
bands in tumour tissue thus showing that these
bands represented phosphorylated forms of
NUCB2.However,52 kDa band in some normal tis-
sue specimens and 55 kDa band in tumours was not
affected by the treatment with phosphatase sug-
gesting that they were derived from an alternative
post-translational modification. No putative N-gly-
cosylation, acethylation, myristoylation or palmi-
toylation sites were found by sequence analysis.
Although NUCB1 has been shown to undergo O-
glycosylation (Lavoie et al. 2002) and 31 Ser and
Thr residues were found in NUCB2 sequence, none
of them were predicted as potential glycosylation
sites by NetOGlyc 3.1 Server.To examine the glyco-
sylation status of NUCB2,the protein extracts were
treated with Sialidase A and O-Glycanase but the
treatment did not result in the shift of mobility
(results not shown). To remove more complex O-
linked structures containing β(1-4)-linked galac-
tose or β-linked N-acetylglucosamine, the extracts
were treated with β(1-4)-Galactosidase and β-N-
Acetylglucosaminidase prior to the O-glycanase
treatment,yet this also did not result in the increase
in mobility of NUCB2 bands.
Localisation of NUCB2 in normal gastric epitheli-
um and gastric lesions 
To determine which cell types express NUCB2 in
normal gastric epithelium and various gastric
lesions,a gastric tissue microarray was stained with
the anti-NUCB2 monoclonal antibody.This demon-
strated that NUCB2 is predominantly localised in
the secretory vesicles of chief cells and at lower lev-
els in the cytoplasm of parietal cells in the stomach
body (Figure 5 A-C), whereas mucous cells were
NUCB2-negative (Figure 5 A, C).
Figure 5. The immunohistochemical analysis of NUCB2 expression in stomach epithelium and gastric lesions. Normal stomach: cardiac
glands (A), oxyntic glands (B) and pyloric glands (C). Chronic atrophic gastritis: mild (D), moderate (E) and severe (F). Gastric adenocar-
cinoma: grade I (G), grade II (H) and grade III (I). Anti-NUCB2 monoclonal antibody was used to stain the tissue sections. NUCB2-speciff-
ic signal was observed in gastric parietal cells (black arrows), chief cells (blue arrows) and plasma cells (red arrows) infiltrated in the
gastritis and gastric cancer tissues while mucous cells do not express NUCB2. No NUCB2 positive tumour cells were detected.In gastritis, NUCB2 expression was found in the
infiltrating plasma cells (Figure 5 E) as well as in
the chief and parietal cells in preserved,presumably
functional glandular structures (Figure 5 D) but it
was lost in atrophic glands (Figure 5 F).Staining of
15 tumour and adjacent normal tissues sections
from the same patients whose tissue specimens
were used for quantitative RT-PCR and Western
blot analyses showed that plasmocytes constituted
the main proportion of NUCB2-positive cells in
tumour tissues while the tumour cells were
NUCB2-negative (Figure 5 G-I). No correlation
with the tumour stage or grade was observed.
Antibodies against NUCB2 are not associated with
anti-parietal cell antibodies
Autoantibodies to acid secreting gastric parietal
cells (GPC) are involved in the aetiology of autoim-
mune and atrophic gastritis that are known to be
precancerous lesions (Correa 1992).Since NUCB2
expression was localised in gastric parietal cells,we
hypothesised that NUCB2 may represent one of the
antigens recognised by anti-parietal cell antibodies
(APCA). As GPC H
+/K
+ ATPase is the dominant
antigen used to detect the presence of APCA, we
expected anti-NUCB2 and anti- H
+/K
+ ATPase anti-
bodies to coincide in the sera from patients with
gastritis and cancer. Four of 13 atrophic gastritis
patients’ and one of 16 gastric cancer patients’
serum samples tested were positive for APCA,how-
ever, none of them had anti-NUCB2 antibodies.
Similarly,the patients having anti-NUCB2 antibod-
ies were negative for APCA thus demonstrating
that induction of anti-NUCB2 response is not asso-
ciated with the autoimmune processes against
GPC.
Discussion
It has been generally assumed that cancer-asso-
ciated expression pattern (expression restricted to
cancers and testis, the cell type from which the
cancer originated, foetal tissues or neurons, over-
expression),and a variety of molecular alterations
including mutations, translocations and splicing
defects may underlie the immunogenicity of
SEREX-defined antigens, however, only in a few
cases such alterations have been found and
demonstrated to induce the immune response
(Chen YT 2004;Tureci et al. 1999; Kalnina et al.
2005; Pfreundschuh 2000). Other mechanisms
that may render tumour cell proteins immuno-
genic are altered posttranslational modifications
(Canelle  et al. 2005;Robinson  et al. 2002;
Brichory et al. 2001), aberrant subcellular locali-
sation resulting for instance from virus infection
(Dong et al. 1994) or altered binding partners of
normal self-proteins, or their localisation on the
surface of apoptotic tumour cells as shown in the
case of β-actin in medullary breast cancer
(Hansen et al. 2001).
In the current study we examined the molecular
alterations that may underlie the IgG responses
against NUCB2 in gastric cancer patients. The
mRNA distribution analysis showed that NUCB2
is expressed in several normal tissues including
spleen, thymus and bone marrow. Usually CD4
+ T
cells recognising antigens that are continuously
present in lymphoid tissues are tolerased
(Zinkernagel and Hengartner 2001; Bos et al.
2005). Since the activation of B cells and Ig class
switch to generate IgG class antibodies requires
signals from activated TH cells, it is unlikely that
the antibodies are directed against the wild-type
NUCB2 protein.Furthermore,NUCB2 mRNA and
protein levels were found to be downregulated in
the majority of gastric tumour tissues when com-
pared to adjacent normal tissues. As the overex-
pression is supposed to be the most frequent
immunogenic stimulus for SEREX-defined anti-
gens,this finding seemed surprising.However,mul-
tiple downregulated antigens eliciting cancer-spe-
cific immune responses have been identified by
SEREX before, including p14.5 in hepatocellular
carcinoma (Stenner-Liewen et al. 2000), Seb4B
and HDAC5 in colon cancer (Scanlan et al. 2002)
and SNT-1/BR-41 in breast cancer (Scanlan et al.
2001).We propose that the immunogenicity of the
downregulated antigens is likely to be elicited by
the alterations at the DNA,mRNA or protein level
resulting in the structural changes of the protein
that may give rise to novel epitopes. Hence, some
of them may turn out to be tumour suppressors.In
fact, the NUCB2 gene is localised to locus
11p15.1-p14, known to be frequently deleted in
ovarian and bladder tumours (Kiechle-Schwarz et
al. 1994; Shaw and Knowles 1995).
In a previous study we searched for somatic
mutations in NUCB2 cDNA by sequencing the
complete protein coding region amplified from the
tumour tissue of the patient with anti-NUCB2
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antibodies. Although several polymorphisms,
including ACA insertion/deletion (Gln 402) were
found, none of them turned out to be somatic
mutations (Line et al. 2002).
Next, we searched for novel splice variants or
transcription initiation sites by applying 5’ RLM-
RACE to three gastric cancer specimens that
resulted in the identification of an alternative dis-
tal promoter and three novel transcript variants
differing in the exon composition at the 5’ end of
the mRNA, yet none of them could encode for a
novel protein isoform. Although the mRNAs tran-
scribed from the newly identified alternative pro-
moter appeared to constitute only a minor frac-
tion of the total NUCB2 mRNA pool, the distal
promoter was considerably more active in gastric
cancers than in the adjacent normal tissues, par-
ticularly in those cases where the total NUCB2
level was strongly downregulated.Hence the usage
of the alternative promoter may represent a com-
pensatory mechanism in tumour cells when the
transcription from the conventional promoter is
shut off. Alternative 5’UTRs have been shown to
play an important role in the post-transcriptional
regulation of gene expression by affecting down-
stream splicing events, translation efficacy, RNA
sorting and localisation (Brevini et al. 2007;
Smith 2008; Cazzola and Skoda 2000; Tsuda et
al. 2000).
In two gastric cancer patient samples, the usage
of the distal promoter correlated with the pres-
ence of 55 and 57-kDa bands detected by Western
blot in gastric tumours but not in adjacent normal
tissues. Dephosphorylation experiments demon-
strated that the 57 kDa band represents phospho-
rylated form of the 55 kDa NUCB2 isoform,which
by itself is likely to represent novel post-transla-
tionally modified isoform.To identify the nature of
the modification, we carried out enzymatic degly-
cosylation, yet this did not affect the mobility of
the 52 kDa band in normal tissues and the 55 kDa
band in tumours. This treatment should remove
most of common O-linked sugars, however it does
not cleave several rare O-linked structures such as
N-acetylgalactosamine found in mucins or man-
nose, for example, therefore the glycosylation of
NUCB2 can not be definitely ruled out. Although
we did not detect any NUCB2-positive cancer cell
by immunohistochemistry, the 55 kDa band was
detected in AGS gastric cancer cells by Western
blotting that implies this isoform is produced by
cancer cells not by plasma cells or the remaining
functional gastric glands yet at the level unde-
tectable by immunohistochemistry. Alterations in
the glycosylation patterns and other post-transla-
tional modifications (PTMs) are frequently found
in various tumours and have been shown to trigger
immune responses to self or tumour proteins
(Ohmori and Kanayama 2005; Suriano et al.
2005; Doyle  et al. 2006; Doyle and Mamula
2005). However it remains to be determined
whether the altered PTM acts as a trigger for the
immune response against NUCB2 and whether the
transcript variant containing the alternative
5’UTR is associated with the altered PTM.
Alternatively, the autoantibody production could
be elicited by the cleavage of NUCB2 during apop-
tosis as it has been demonstrated for apoptotic
cleavage product of BARD1 (Gautier et al.
2000). In fact, NUCB2 was recently shown to be
cleaved by caspases and the cleavage sites are
located at one of the EF-hand motifs (Figure 1)
(Valencia et al. 2008).
The identification of multiple functionally unre-
lated interaction partners and their implication in
various processes such as Ca
2+ homeostasis (Kroll
et al. 1999;Morel-Huaux et al. 2002;Taniguchi et
al. 2000; Lin et al. 1999), Gα protein mediated
signalling (Lin et al. 2000), unfolded protein
response (Tsukumo et al. 2007),TNFR1 shedding
(Islam et al. 2006) and hypothalamic feeding reg-
ulation (Oh et al. 2006; Nonogaki et al. 2008)
suggests that nucleobindins are multifunctional
proteins having various tissue-specific functions.
So far, nothing is known about their function in
stomach. The staining of stomach tissue sections
with anti-NUCB2 antibody revealed its expression
in the chief cells and parietal cells but not in
mucous and muscle cells while it is not clear
whether it is expressed in G and ECL cells. The
main function of chief and parietal cells is the
secretion of pepsinogens and gastric acid, respec-
tively. Both secretion processes are coupled and
mediated by the intracellular Ca
2+ signalling (Hou
and Schubert 2006; Remy et al. 2007; Kimura et
al. 2001; Gritti et al. 2000). The localisation of
NUCB2 in the secretory granules of chief cells and
its loss in atrophic glands suggests a role in the
secretion processes by establishing an agonist-
releasable Ca
2+ store in ER or Golgi apparatus,sig-
nalling via heterotrimeric Gα proteins and/or medi-
ating the exocytosis of the secretory granules.It also would be of interest to investigate
whether the nesfatin 1,the 1-82 aa peptide gener-
ated by a proteolytic cleavage of NUCB2 in hypo-
thalamus recently shown to act as a satiety mole-
cule via the serotonin system (Oh et al. 2006;
Nonogaki  et al. 2008), is also processed and
secreted in gastric mucosa as it was shown for
other hypothalamic peptides that regulate food
intake.
Furthermore, NUCB2 has been shown to have
an essential role in the generation of soluble extra-
cellular TNF receptors (TNFR1) through binding
to ARTS-1 (aminopeptidase regulator of TNFR1
shedding) extracellular domain in a calcium-
dependent manner, at least in vascular endothelial
cells (Islam et al. 2006). If the same mechanism
is operational in the parietal cells, the loss of
NUCB2 expression during the progression of gas-
tritis would abolish TNFR1 release, thereby ren-
dering the parietal cells more susceptible to TNF-
α induced apoptosis and thus increasing the sever-
ity of atrophy and inflammation.
In summary, we made an attempt to elucidate
the molecular mechanism underlying NUCB2
immunogenicity in gastric cancer patients. Novel
transcript variants differentially expressed in can-
cerous tissues and a novel cancer-associated post-
translationally modified NUCB2 isoform were
identified, however, no conclusive evidence was
gained to prove their association with the
immunogenicity of NUCB2. Nevertheless, this
study for the first time gained an insight into the
physiological functions of NUCB2 in the stomach
– it showed that NUCB2 is phosphorylated and
expressed in the secretory granules of chief cells
and in the cytoplasm of parietal cells in the func-
tioning gastric glands and further we propose the
potential role of NUCB2 in the signalling leading
to the secretion of gastric acid and pepsinogens.It
also would be of interest to investigate whether
the loss of NUCB2 is implicated in the progression
of inflammation and atrophy mediated by TNF
signalling.
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